Puma Biotechnology (PBYI) Stock Price, Quote & News

Company Profile

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It develops alisertib, a small molecule inhibitor of aurora kinase A for the...

Industry: Biotechnology

Sector: Healthcare

Phone: 424 248 6500

Website: www.pumabiotechnology.com

Address:

10880 Wilshire Boulevard, Suite 2150, Los Angeles, United States

bigpharmaMM Sep. 14 at 12:46 AM

$PBYI hear that?

0 · Reply

Cinderella74 Sep. 11 at 5:33 PM

$PBYI the crash is coming.

2 · Reply

Gator5326 Sep. 8 at 8:51 PM

$PBYI Johnny, you shorting again?

2 · Reply

Jonnyking Sep. 8 at 7:59 PM

$PBYI this will go under 4 and then 3 before next er and ALan will not do anything to save us

0 · Reply

Gator5326 Sep. 8 at 7:43 PM

$PBYI Very rushed presentation with NO questions after. Is there no institutional interest?

2 · Reply

Jonnyking Sep. 8 at 4:58 PM

$PBYI we need some serious news

0 · Reply

Cinderella74 Sep. 8 at 3:22 PM

$PBYI target 4,1.

0 · Reply

PSDL75 Sep. 8 at 2:47 PM

$PBYI $MGNX price action on Bios suggests sell the potential news with all these conferences?

0 · Reply

Cinderella74 Sep. 8 at 2:39 PM

$PBYI the volume is big. The bad news is coming.

0 · Reply

Jonnyking Sep. 8 at 2:11 PM

$PBYI wow

3 · Reply

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Sep 2, 2025, 4:07 PM EDT - 11 days ago

Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 8:53 PM EDT - 5 weeks ago

Puma Biotechnology, Inc. (PBYI) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

Puma Biotechnology Reports Second Quarter Financial Results

Jul 24, 2025, 4:15 PM EDT - 7 weeks ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results

Jun 25, 2025, 11:06 AM EDT - 2 months ago

Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

May 9, 2025, 9:08 AM EDT - 4 months ago

Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 4 months ago

Puma Biotechnology Reports First Quarter Financial Results

Apr 30, 2025, 6:00 AM EDT - 4 months ago

Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients

Apr 28, 2025, 3:03 PM EDT - 4 months ago

Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025

Apr 24, 2025, 4:11 PM EDT - 5 months ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results

Mar 31, 2025, 4:53 AM EDT - 5 months ago

Puma SE: Undervalued With Tailwinds Ahead

Mar 26, 2025, 9:00 AM EDT - 6 months ago

Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025

Mar 21, 2025, 7:46 AM EDT - 6 months ago

PUMA SE: This Is The Right Time To Buy

Mar 5, 2025, 5:30 PM EST - 6 months ago

Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference

Feb 27, 2025, 9:02 PM EST - 7 months ago

Puma Biotechnology, Inc. (PBYI) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:05 PM EST - 7 months ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 4:15 PM EST - 7 months ago

Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference

Feb 13, 2025, 4:15 PM EST - 7 months ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results

Dec 23, 2024, 9:01 AM EST - 9 months ago

Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation

Dec 16, 2024, 11:36 AM EST - 9 months ago

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Nov 20, 2024, 8:57 AM EST - 10 months ago

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

Nov 7, 2024, 11:09 PM EST - 11 months ago

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:05 PM EST - 11 months ago

Puma Biotechnology Reports Third Quarter 2024 Financial Results

Oct 24, 2024, 4:07 PM EDT - 11 months ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

Sep 3, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 10:54 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Jul 18, 2024, 4:10 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

Jun 3, 2024, 2:33 PM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

Jun 2, 2024, 10:01 AM EDT - 1 year ago

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

May 28, 2024, 9:00 AM EDT - 1 year ago

Puma Biotechnology to Join Russell 3000 Index

May 23, 2024, 5:15 PM EDT - 1 year ago

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

May 2, 2024, 10:11 PM EDT - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Apr 18, 2024, 4:15 PM EDT - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

Mar 20, 2024, 8:30 AM EDT - 1 year ago

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Feb 29, 2024, 8:39 PM EST - 1 year ago

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Feb 29, 2024, 4:05 PM EST - 1 year ago

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 22, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

Feb 15, 2024, 4:10 PM EST - 1 year ago

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

Feb 13, 2024, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

Jan 11, 2024, 4:07 PM EST - 1 year ago

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

Dec 14, 2023, 1:41 AM EST - 1 year ago

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Dec 11, 2023, 8:30 AM EST - 1 year ago

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

Nov 2, 2023, 10:21 PM EDT - 2 years ago

Puma Biotechnology, Inc. (PBYI) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Puma Biotechnology Reports Third Quarter 2023 Financial Results

Oct 19, 2023, 4:14 PM EDT - 2 years ago

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

Sep 21, 2023, 4:10 PM EDT - 2 years ago

Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer

Aug 31, 2023, 4:07 PM EDT - 2 years ago

Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference

bigpharmaMM Sep. 14 at 12:46 AM

$PBYI hear that?

0 · Reply

Cinderella74 Sep. 11 at 5:33 PM

$PBYI the crash is coming.

2 · Reply

Gator5326 Sep. 8 at 8:51 PM

$PBYI Johnny, you shorting again?

2 · Reply

Jonnyking Sep. 8 at 7:59 PM

$PBYI this will go under 4 and then 3 before next er and ALan will not do anything to save us

0 · Reply

Gator5326 Sep. 8 at 7:43 PM

$PBYI Very rushed presentation with NO questions after. Is there no institutional interest?

2 · Reply

Jonnyking Sep. 8 at 4:58 PM

$PBYI we need some serious news

0 · Reply

Cinderella74 Sep. 8 at 3:22 PM

$PBYI target 4,1.

0 · Reply

PSDL75 Sep. 8 at 2:47 PM

$PBYI $MGNX price action on Bios suggests sell the potential news with all these conferences?

0 · Reply

Cinderella74 Sep. 8 at 2:39 PM

$PBYI the volume is big. The bad news is coming.

0 · Reply

Jonnyking Sep. 8 at 2:11 PM

$PBYI wow

3 · Reply

PMD777 Sep. 8 at 11:15 AM

$PBYI why is this showing $5.50 - that doesn't appear to have printed.

0 · Reply

NVDAMillionaire Sep. 5 at 9:31 PM

$PBYI Great piece that accurately captures PBYI's current position. So if you want to refresh your understanding of PBYI or learn about PBYI for the first time, this is essential reading. https://beyondspx.com/quote/PBYI/puma-biotechnology-unlocking-value-through-targeted-oncology-and-fiscal-discipline-nasdaq-pbyi#analysis

1 · Reply

bulltradz Sep. 1 at 6:27 PM

$PBYI happy Labor Day bull broz letz pop into fall

1 · Reply

Y0umadBro Aug. 28 at 12:28 PM

$PBYI

0 · Reply

bulltradz Aug. 26 at 8:00 PM

$PBYI holding nicly for a pop

1 · Reply

Wealthy500 Aug. 23 at 1:41 AM

$PBYI p.e. is just under 6. 18 or 24 p.e. multiply price by 3 - 4 to get fair price . 15-20$.

0 · Reply

RadioIsotope25 Aug. 22 at 12:51 PM

$RADX Lantheus bought more at $11.70 in the first quarter. Worth that minimum. All this movement under that price is mispriced stock action. Lantheus is the crème de la crème in Radiopharma. This could be at $35 dollars in October. Even at $35 the market cap is still small compared to Clarity or Telix. Jones isn’t far off with this prediction at $30. Dealflow insane in this niche. $PBYI $AVDL $IOVA

1 · Reply

Unicorn2020 Aug. 21 at 6:46 PM

$PBYI Did you buy back below $5.00? I did. So $6.00 is coming soon. Yayyyy.

1 · Reply

Jonnyking Aug. 21 at 6:11 PM

$PBYI we should head back to 6 tomorrow, 8 by end of month, 10 end of September, 12 by October and sell for 40 dollars a share after positive strong phase 2 data end of year

1 · Reply

free2dream Aug. 21 at 1:51 PM

$PBYI $250 market cap is an insult. Should be around $2B

2 · Reply

Y0umadBro Aug. 20 at 2:21 PM

$PBYI entire market down, thus holding up well actually

1 · Reply

Whiskey1679 Aug. 19 at 11:27 PM

Whiskey's Penny Picks out tomorrow by 6:20 am PDT!! Trending: $FLNT $PPCB $PBYI $CLRO $XAGE

1 · Reply

Market Cap	225.16M
Revenue (ttm)	230.47M
Net Income (ttm)	30.28M
EPS (ttm)	N/A
PE Ratio	4.59
Forward PE	8.65
Profit Margin	13.14%
Debt to Equity Ratio	0.43

Volume	377,400
Avg Vol	619,638
Day's Range	N/A - N/A
Shares Out	50.37M
Stochastic %K	6%
Beta	1.38
Analysts	Hold
Price Target	$3.00